Info: Read More
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • How to Order
  • Delivery time
  • Science | Nature | Cell | View More
    Bioactive Products
    Inhibitors Compound Library
    A unique collection of 267 Inhibitor natural compounds
    Catalog No: Bb221 Inhibitors Compound Library
    Screening Details
    Size: 1mg/well * 267 Compounds
    2mg/well * 267 Compounds
    Cat. No. Information
    CFN99757 Isorhamnetin-3-O-beta-D-Glucoside

    Isorhamnetine-3-O-rutinoside inhibits the activity of alpha-glucosidase from rat intestine; it exhibits a potent rat lens aldose reductase (RLAR) inhibition in vitro, its IC(50) being 1.4 microM and has inhibitory effects of sorbitol accumulation, suggests that it is a leading compound for further study as a new drug for the prevention and/or treatment of diabetes and its complications.
    CFN99765 Catharanthine

    Catharanthine inhibits nicotinic receptor mediated diaphragm contractions with IC50 of 59.6 μM, it dilates small mesenteric arteries and decreases heart rate and cardiac contractility by inhibition of voltage-operated calcium channels on vascular smooth muscle cells and cardiomyocytes.
    CFN99681 Lupenone

    Lupenone and lupeol inhibit protein tyrosine phosphatase 1B (PTP1B) with IC50 values of 13.7 ± 2.1 and 5.6 ± 0.9 uM, respectively, they are non−competitive inhibitors of PTP1B, and PTP1B appears to be an attractive target for the development of new drugs for type 2 diabetes and obesity. Lupenone stimulates melanogenesis by increasing the tyrosinase enzyme expression via mitogen-activated protein kinase phosphorylated extracellular signal-regulated kinases 1 and 2 phosphorylation inhibition. A 1 : 4 mixture of Lupenone and caryophyllene oxide shows trypanocidal activity.
    CFN99693 Calyxin B

    Calyxin B exhibits potent activity against human HT-1080 fibrosarcoma cells with an ED50 value of 0.69 microM. A methylated product of calyxin A and an epimeric mixture of Calyxin B, showed greatly reduced activity suggesting that phenolic hydroxyl groups are involved in the inhibitory activity.
    CFN99694 Brevilin A

    Brevilin A is a strong impetus for the development of selective JAK-STAT inhibitors and therapeutic drugs in order to improve survival of patients with hyperactivated JAKs and STATs. Brevilin A shows antigiardial activity (IC50 = 16.1 μM) and is similarly active in vitro against Entamoeba histolytica (IC50 between 4.5 and 9 μM) and against Plasmodium falciparum (IC50 = 9.42 μM).